Roche Holding Ag Stock Earnings Reports

Roche reported strong full-year 2025 results: group sales grew 7% (Pharma +9%, Diagnostics +2%; Diagnostics would have been +7% excluding China pricing reforms). Core operating profit rose 13% and core EPS increased 11% (tax headwinds restrained EPS upside). Management reiterated 2026 guidance: mid-single-digit sales growth and high single-digit core EPS growth, and indicated continued dividend increases in CHF. Key commercial drivers: Vabysmo, Ocrevus (notably subcutaneous uptake), Xolair, Phesgo, Polivy, Gazyva expansion into immunology, and continued growth in hematology and neurology franchises. Diagnostics launched new products (AXELIOS sequencing solution, automated mass spec, dengue and BV/CV assays) and will prioritize margin recovery as China headwinds abate in 2026–2027. Pipeline momentum was the centerpiece: multiple positive Phase III/II readouts in Q4 (fenebrutinib in MS, giredestrant lidERA/evERA in breast cancer, CT-388 in obesity, Enspryng, Gazyva in new indications, etc.), 10 NMEs advanced into Phase III (a company record), and ~19 potential launches planned by 2030. Roche also announced a binding agreement with the U.S. government that includes a commitment to invest $50 billion in the U.S. over five years in exchange for tariff and demo-project exemptions and some Medicaid rebate provisions. Cash flow was lower in 2025 (CHF 16.2bn) due to higher receivables, inventories (tariff mitigation), and elevated intangible/M&A spend (CHF ~5.1bn), but management expects a stronger cash year in 2026 and reduced net debt. Key near-term catalysts for investors: persevERA (giredestrant first-line) readout, FENhance 1 (fenebrutinib RMS) readout, multiple Phase II/III readouts (divarasib, Itovebi, CT-388, CT-868, Enspryng MOG-AD), and the commercial scaling of AXELIOS sequencing and CGM diagnostics.